Cholesterol

Cholesterol test
#Cholesterol #Drug development #Heart disease #University of California San Diego

Hidden pathway could be targeted to reduce heart disease 

A hidden biological pathway could be targeted to reduce cholesterol-related heart disease, research shows.  A team from the University of California San Diego School of Medicine uncovered a biological pathway involving the liver, explaining why high-cholesterol diets impede the body’s ability to clear harmful low-density lipoprotein (LDL)… Read More

#News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Cholesterol test
#Cardiovascular disease #Cholesterol #Eli Lilly #Gene therapy

Single-shot gene therapy could cut cholesterol by 62% 

A single-shot gene therapy could slash cholesterol levels by 62%, potentially ‘transforming cardiovascular care’.  Results from the Heart-2 study into VERVE-102, published in The New England Journal of Medicine, showed reductions of up to 62% in a cohort of 35 participants, with durability observed for up… Read More

#News

CRISPR gene editing
#Cardiovascular disease #Cholesterol #CRISPR #CRISPR Therapeutics #CRISPR-Cas9 #Phase I trial

In vivo CRISPR gene editing therapy lowers cholesterol

CRISPR Therapeutics has shared positive Phase I data from an ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3.   A single-course treatment with CTX310 produced dose-dependent, durable reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum… Read More

#News #Trending News

Cholesterol test
#Cholesterol #Japan

Nexletol receives regulatory approval in Japan

 Hypercholesterolaemia treatment Nexletol has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare.  The announcement was made by US pharmaceutical company Esperion, whose partner Otsuka Pharmaceutical has developed and commercialised Nexletol. The product is a treatment for hypercholesterolaemia and familial hypercholesterolaemia. … Read More

#News

Cryptosporidium parasite
#Cholesterol #Drug repurposing #Parasitic disease #The Francis Crick Institute

Abandoned drug could treat a neglected parasitic infection

Investigators have found evidence that the cholesterol-lowering drug lapaquistat could be an effective treatment for Cryptosporidium, an intestinal parasite.  Researchers at the Francis Crick Institute in London, UK, have mapped the human metabolic pathways that Cryptosporidium requires to survive.  The scientists say that shutting down… Read More

#News

Heart attack patient with doctor
#Cardiovascular disease #Cholesterol #Heart attack #Imperial College London #Lund University #Statins

Statins and ezetimibe combination could prevent heart attacks

A new study from researchers at Lund University in Sweden and Imperial College London suggests that treating patients earlier with a combination of statins and the cholesterol-lowering drug ezetimibe could prevent thousands of new heart attacks.  For those who survive a heart attack, the risk of a… Read More

#News

Cholesterol test
#AstraZeneca #Cardiovascular disease #Cholesterol #Clinical trial

PCSK9 inhibitor demonstrates significant cholesterol reduction

Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 have demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy.  AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite… Read More

#News